SELLAS Life Sciences Group, Inc.
Conduct final analysis of the REGAL clinical trial
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 14 Nov 2022
- Due
- 31 Dec 2024
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The targeted number of events (deaths) for the final analysis will be reduced to 80 from 105 and is currently expected to occur by the end of 2024.”
What we found
Evidence strength A What the grades mean
The company did not conduct the final analysis by the end of 2024; as of December 2025, only 72 of the required 80 events had been reached.
-
A SELLAS Life Sciences Group, Inc. 10-K filed 2026-03-19
“In December 2025, we announced that our contract research organization informed us that the pooled number of events was 72 as of December 26, 2025.” ✓ confirmed on the page
Market reaction: the shares moved +11.3% against the S&P 500 over the three sessions around the disclosure (18 Mar 2026 to 23 Mar 2026). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +365 days
- Scope drift 0.0%
- 2 versions
-
Version 1 · original · stated 14 Nov 2022
Deadline 31 Dec 2024 (“by the end of 2024”) · target 80 events · wording expected
-
Version 2 · stated 20 Mar 2025
Deadline 31 Dec 2025 (“in 2025”) · target 80 events · wording expected
“Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Conduct
- Deliverable
- Final analysis of REGAL study
- Target
- 80 events
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory, Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-SLS-002001 · Corrections policy